Literature DB >> 25106108

The mechanism of honokiol-induced intracellular Ca(2+) rises and apoptosis in human glioblastoma cells.

Wei-Zhe Liang1, Chiang-Ting Chou2, Hong-Tai Chang3, Jin-Shiung Cheng4, Daih-Huang Kuo5, Kuang-Chung Ko6, Ni-Na Chiang7, Ru-Fang Wu8, Pochuen Shieh5, Chung-Ren Jan9.   

Abstract

Honokiol, an active constituent of oriental medicinal herb Magnolia officinalis, caused Ca(2+) mobilization and apoptosis in different cancer cells. In vivo, honokiol crossed the blood-brain or -cerebrospinal fluid barrier, suggesting that it may be an effective drug for the treatment of brain tumors, including glioblastoma. This study examined the effect of honokiol on intracellular Ca(2+) concentration ([Ca(2+)]i) and apoptosis in DBTRG-05MG human glioblastoma cells. Honokiol concentration-dependently induced a [Ca(2+)]i rise. The signal was decreased partially by removal of extracellular Ca(2+). Honokiol-triggered [Ca(2+)]i rise was not suppressed by store-operated Ca(2+) channel blockers (nifedipine, econazole, SK&F96365) and the protein kinase C (PKC) activator phorbol 12-myristate 13 acetate (PMA), but was inhibited by the PKC inhibitor GF109203X. GF109203X-induced inhibition was not altered by removal of extracellular Ca(2+). In Ca(2+)-free medium, pretreatment with the endoplasmic reticulum Ca(2+) pump inhibitor thapsigargin (TG) or 2,5-di-tert-butylhydroquinone (BHQ) abolished honokiol-induced [Ca(2+)]i rise. Conversely, incubation with honokiol abolished TG or BHQ-induced [Ca(2+)]i rise. Inhibition of phospholipase C (PLC) with U73122 abolished honokiol-induced [Ca(2+)]i rise. Honokiol (20-80μM) reduced the cell viability, which was not reversed by prechelating cytosolic Ca(2+) with BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester). Honokiol (20-60μM) enhanced reactive oxygen species (ROS) production, decreased mitochondrial membrane potential, released cytochrome c, and activated caspase-9/caspase-3. Together, honokiol induced a [Ca(2+)]i rise by inducing PLC-dependent Ca(2+) release from the endoplasmic reticulum and Ca(2+) entry via PKC-dependent, non store-operated Ca(2+) channels. Moreover, honokiol activated the mitochondrial pathway of apoptosis in DBTRG-05MG human glioblastoma cells.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Ca(2+); Honokiol; Human glioblastoma cells; Mitochondrial membrane potential

Mesh:

Substances:

Year:  2014        PMID: 25106108     DOI: 10.1016/j.cbi.2014.07.012

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  6 in total

1.  Honokiol induces cell cycle arrest and apoptosis in human gastric carcinoma MGC-803 cell line.

Authors:  Bin Yan; Zhi-Yong Peng
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Honokiol induces cell cycle arrest and apoptosis via p53 activation in H4 human neuroglioma cells.

Authors:  Yun-Bao Guo; Xin-Jie Bao; Song-Bai Xu; Xing-Dong Zhang; Hai-Yan Liu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

3.  Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling.

Authors:  Shujie Cheng; Victor Castillo; Isaac Eliaz; Daniel Sliva
Journal:  Int J Oncol       Date:  2015-04-02       Impact factor: 5.650

4.  Enhanced oral bioavailability of magnolol via mixed micelles and nanosuspensions based on Soluplus®-Poloxamer 188.

Authors:  Guoyuan Li; Yuting Lu; Yongchun Fan; Qing Ning; Weiguang Li
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 5.  Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.

Authors:  Lalita Guntuku; V G M Naidu; Veera Ganesh Yerra
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

6.  Magnolol and honokiol exert a synergistic anti-tumor effect through autophagy and apoptosis in human glioblastomas.

Authors:  Yu-Chen Cheng; Dueng-Yuan Hueng; Hua-Yin Huang; Jang-Yi Chen; Ying Chen
Journal:  Oncotarget       Date:  2016-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.